Carlos Moedas (age 44) studied engineering at Lisbon University, Portugal and an MBA at Harvard University, USA. He worked for Goldman Sachs and EuroHypo investment bank before returning to Portugal in 2004 to join a property consulting company, and established his own property investment company in 2008. He led negotiations for the Social Democratic Party (PSD) for Portugal’s 2011 State Budget. He was elected as an MP in the same year, and leading implementation of the (...)
The fifth international influenza conference organised by EPHA member the European Scientific Working Group on Influenza (ESWI) took place in Riga on 14-17 September. A number of plenary and ’science/policy interface’ sessions examined the issue of low vaccination uptake in many Member States, as well as other issues related to pandemic preparedness and communication aspects of influenza-related health threats.
In the opening plenary, ’Why should influenza be a public (...)
Vaccines and Immunization
On 15 December 2011, the European Food Safety Authority (EFSA) Management Board adopted its Authority’s Policy on independence and scientific decision-making processes. A few months later EFSA’s Executive Director signed off a set of implementing rules on Declarations of Interests (DoIs). These rules regulate the way EFSA should process DoIs and prevent the occurrence of conflicts of interests.
The current system of declarations of interests and their subsequent (...)
Active Citizenship Network (ACN) decided to dedicate the 8th celebration of European Patients’ Rights Day in 2014 to "the role of citizens’ organisations in the empowerment of patients with chronic diseases." On 12 May, speakers examined the different chronic disease networks (e.g. cancer, diabetes, chronic obstructive pulmonary disease(COPD)) and their impacts on political decision making. On 13 May, EPHA participated in the panel discussion on how research policy can respond (...)
Brussels, 3 April 2014 – EPHA welcomes the majority of the measures adopted yesterday by the European Parliament as part of the revision of the EU Medical Devices Directive (MDD) and the In Vitro Diagnostic Medical Devices (IVD) Directive. After a year and a half of proposals (1) and in-depth discussions, it is time to rebuild the trust of patients around Europe.
“As the protection of patient safety is a paramount objective, the European Parliament has today taken a (...)
This position paper, supported by 23 leading Global Health NGOs from both sides of the Atlantic, calls on both public and private stakeholders to ensure that R&D investment targets for poverty-related and neglected diseases (PRNDs) are guaranteed and strongly supported across the board.
Research and innovation are critical components in the right to health for all
While everybody recognises that health is an essential precondition for development, the research and innovation (...)
EPHA is organising a joint debate about the pivotal role that patients should play in creating innovative, affordable and quality technologies and products for poverty-related and neglected diseases.
To register, please RSVP with your full name and contact details at firstname.lastname@example.org by March 6th.
The European Commission introduced its proposal for a revision of the data protection regulations of the EU two years ago, yet despite agreement on a compromise text by the European Parliament in October 2013, completion of a finalised General Data Protection Regulation (GDPR) has now been delayed until after the May elections.
An agreement reached on 22 January between EU Justice Commissioner, Vivian Reding, and representatives of the Greek and incoming Italian Presidency, has set the new (...)
The European Partnership for Action Against Cancer (EPAAC) was launched in 2009, after the European Commission published its Communication on Action Against Cancer: European Partnership. Although this Joint Action will end in 2013, participants are committed to continue the work apart from 2014, under a renewed mandate.
What is the EPAAC all about?
After circulatory diseases, cancer was the second most common cause of death in 2006, accounting for two out of ten deaths in women and (...)
The European Commission has recently published a Staff Working Document (SWD) exploring the potential of Personalised Medicine, reporting on recent developments in the EU legislation, as well as looking at the factors affecting the uptake of personalised medicine in healthcare systems.
Personalised Medicine is now more close to be effective to patients, which means that treatments can be designed taking into account a specific patient group and hence able to tackle the problem with the (...)
Access to Medicines
Health Rights and Patients
Pharmaceuticals and Medicines